Pfizer Inc. Stock
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.600% | -1.505% | 3.698% | 2.201% | 1.457% | -35.648% | -39.046% |
| BioMarin Pharmaceutical Inc. | 2.450% | 0.192% | 3.489% | 3.860% | 2.554% | -34.323% | -20.232% |
| Biogen Inc. | -0.210% | -1.244% | 0.068% | 58.750% | 18.652% | -27.310% | -35.638% |
| Zoetis Inc. A | 2.230% | -0.927% | -3.128% | -48.819% | -38.264% | -61.488% | -61.677% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
3 Absurdly Cheap Dividend Stocks to Buy Before August
When it comes to high-yield dividend stocks, it's not a matter of quantity, but of quality. There are numerous stocks with forward dividend yields of 5% or higher, but many of them are firmly in the
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.
Pfizer (NYSE: PFE) has a shockingly high dividend yield of 6.8%. The S&P 500 Index (SNPINDEX: ^GSPC) has a 1% yield, and the average pharmaceutical stock's yield is roughly 1.5%. Given that huge
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring
BioNTech (NASDAQ: BNTX) rose to prominence several years ago thanks to its role in the coronavirus market. The company developed Comirnaty, one of the best-selling COVID-19 vaccines, with Pfizer